Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE45.8250
- TODAY'S CHANGE (%)0.2150 (0.4714%)
- Bid / Lots45.7900/ 2
- Ask / Lots45.8600/ 6
- Open / Previous Close45.6100 / 45.6100
- Day Range
- 52 Week Range
- Volume220,569
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 3989 | 45.14 |
| 09:36 ET | 36100 | 45.26 |
| 09:38 ET | 700 | 45.22 |
| 09:39 ET | 868 | 45.19 |
| 09:41 ET | 2669 | 45.405 |
| 09:43 ET | 200 | 45.41 |
| 09:45 ET | 2264 | 45.395 |
| 09:48 ET | 3203 | 45.84 |
| 09:50 ET | 1380 | 45.745 |
| 09:52 ET | 500 | 45.75 |
| 09:54 ET | 200 | 45.72 |
| 09:56 ET | 900 | 45.61 |
| 09:57 ET | 1300 | 45.575 |
| 09:59 ET | 707 | 45.58 |
| 10:01 ET | 200 | 45.595 |
| 10:03 ET | 2372 | 45.37 |
| 10:06 ET | 1500 | 45.71 |
| 10:08 ET | 900 | 45.7 |
| 10:10 ET | 100 | 45.75 |
| 10:12 ET | 1900 | 45.745 |
| 10:14 ET | 876 | 45.71 |
| 10:15 ET | 2179 | 45.93 |
| 10:17 ET | 100 | 45.94 |
| 10:19 ET | 2543 | 46 |
| 10:21 ET | 5183 | 45.95 |
| 10:24 ET | 400 | 46.005 |
| 10:26 ET | 500 | 46 |
| 10:28 ET | 300 | 46 |
| 10:30 ET | 4506 | 46.03 |
| 10:32 ET | 533 | 46.03 |
| 10:33 ET | 100 | 46.07 |
| 10:35 ET | 2935 | 46.1137 |
| 10:37 ET | 630 | 46.105 |
| 10:39 ET | 585 | 46.05 |
| 10:42 ET | 100 | 46.03 |
| 10:44 ET | 200 | 46.1181 |
| 10:46 ET | 36180 | 45.79 |
| 10:50 ET | 200 | 45.67 |
| 10:51 ET | 909 | 45.61 |
| 10:53 ET | 8928 | 45.47 |
| 10:55 ET | 700 | 45.765 |
| 10:57 ET | 778 | 45.77 |
| 11:00 ET | 400 | 45.765 |
| 11:02 ET | 300 | 45.705 |
| 11:04 ET | 2847 | 45.625 |
| 11:06 ET | 2897 | 45.72 |
| 11:08 ET | 100 | 45.7 |
| 11:09 ET | 1449 | 45.77 |
| 11:11 ET | 100 | 45.77 |
| 11:13 ET | 1500 | 45.785 |
| 11:15 ET | 200 | 45.74 |
| 11:20 ET | 100 | 45.83 |
| 11:22 ET | 200 | 45.79 |
| 11:24 ET | 39347 | 46.005 |
| 11:26 ET | 900 | 46.125 |
| 11:27 ET | 4543 | 45.94 |
| 11:29 ET | 1327 | 45.945 |
| 11:31 ET | 100 | 45.91 |
| 11:33 ET | 300 | 45.902 |
| 11:36 ET | 2936 | 45.825 |
Sep 27, 2024
DJ Agios Pharmaceuticals Down Over 6%, on Pace for Largest Percent Decrease Since September 2022 -- Data Talk, from 1:36PM ET on Friday Sep 27, 2024 by Dow Jones
1:36PM ET on Friday Sep 27, 2024 by Dow JonesDJ Agios Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners, from 7:40AM ET on Friday Sep 27, 2024 by Dow Jones
7:40AM ET on Friday Sep 27, 2024 by Dow Jones
Sep 19, 2024
DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 11, 2024
DJ Agios Gets FDA Orphan Designation for Tebapivat in Myelodysplastic Syndromes, from 7:28AM ET on Wednesday Sep 11, 2024 by Dow Jones
7:28AM ET on Wednesday Sep 11, 2024 by Dow JonesAgios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS), from 7:00AM ET on Wednesday Sep 11, 2024 by Dow Jones
7:00AM ET on Wednesday Sep 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 2.7B | -7.1x | --- |
Janux Therapeutics Inc | 2.6B | -50.8x | --- |
Geron Corp | 2.7B | -12.7x | --- |
SpringWorks Therapeutics Inc | 2.8B | -7.3x | --- |
Protagonist Therapeutics Inc | 2.8B | 17.1x | --- |
Immunitybio Inc | 2.5B | -4.1x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
|---|---|
Revenue (TTM) | $31.3M |
Shares Outstanding | 56.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-6.49 |
Book Value | $14.50 |
P/E Ratio | -7.1x |
Price/Sales (TTM) | 84.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,293.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
